SG/CALL/ELI LILLY & CO/1050/0.1/20.12.24 | Real-time Bid/Ask 04:47:13 13/05/2024 pm IST | ||
| 1.27 EUR / 1.3 EUR | -8.87% |
|
| Current month | +15.57% | ||
| 1 month | -19.43% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ELI LILLY AND COMPANY
Latest news about ELI LILLY AND COMPANY
| Date | Price | Change | Volume |
|---|---|---|---|
| 13/24/13 | 1.29 | -8.51% | 0 |
| 10/24/10 | 1.41 | -4.08% | 0 |
| 09/24/09 | 1.47 | -0.68% | 0 |
| 08/24/08 | 1.48 | +18.40% | 0 |
| 07/24/07 | 1.25 | +25.00% | 0 |
Delayed Quote Börse Stuttgart
Last update May 13, 2024 at 01:41 pm IST
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | ELI LILLY AND COMPANY |
| Issuer | 
Société Générale
|
| WKN | SW7EQ5 |
| ISIN | DE000SW7EQ59 |
| Date issued | 07/03/2024 |
| Strike | 1,050 $ |
| Maturity | 20/12/2024 (221 Days) |
| Parity | 10 : 1 |
| Emission price | 2.62 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 2.58 € |
|---|---|
| Lowest since issue | 1 € |
| Spread | 0.03 € |
| Spread % | 2.31% |
Company Profile
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows:
- endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems;
- oncology (19.5%);
- immunology diseases (11.1%);
- neurology (8.4%): primarily drugs used in treating depression and schizophrenia;
- other (3.3%).
Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).
Sector
-
Consensus: Eli Lilly and Company
Sell
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
760
USD
Average target price
850.4
USD
Spread / Average Target
+11.90%
- Stock Market
- Warrants
- Warrant